TrialNature communications2024

Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.

Gilles Freyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.